In AML, the MYC proto-oncogene negatively regulates the expression and function of TFEB, that exerts a tumor suppressor role through upregulation of the isocitrate dehydrogenase (IDH)1/IDH2-Tet methylcytosine dioxygenase 2 (TET2) axis, resulting in global 5-methycytosine hydroxylation, blast differentiation and death [80]. The gene discussed is TET2; the disease is acute myeloid leukemia.